Login
Login     |     Register     |     Recover Username/Password

General Investing

Ares Capital Corp. (ARCC) and Apollo Investment Corp. (AINV) are Among Best in BDC Space

December 14, 2012

Ares Capital Corp. (ARCC) is one of the easiest ways to play into the business development companies, or BDC space, in the current environment of good technical drivers, fundamental and macroeconomic drivers, and the BDC placement in the investment cycle, says Jasper Burch, Research Analyst at Macquarie Group Limited.

“[ARCC is] the largest, probably the BDC with the best reputation, definitely one of the best management teams, very well established track record. It’s a fundamentally safe company to investors. That doesn’t mean you won’t get share price volatility, and there is always risk whenever you’re investing in equities, but the fundamental driver of the company makes it a very attractive easy way to play the space,” Burch said.

Another name Burch likes on valuation is Apollo Investment Corp. (AINV). AINV is a turnaround story, he says, and the company has brought in new management to move from lower-yielding securities into more senior, higher-yielding securities. The company currently trades on a lower valuation than peers, near book value.

“What I like about it is it’s a story where there’s a greater growth story in that name than I think lot of its peers, and the reason I say that is the major theme is recycling of the portfolio from a more of a liquid portfolio into a more high-touch middle market portfolio that should give better risk-adjusted returns,” Burch said.

“Those are the two that really stand out to me right now. Ares is a really large, safe, well established company, and then Apollo is a little bit more of turnaround in growth story, but still a very strong company,” he said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now